Get started
Work

921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer

Year: 2023
Type: article
DOI: 10.1016/j.annonc.2023.09.2065
Authors: L. Nabell, A.L. Ho, M.R. Posner, P. Neupane, A-R. Naqash, S. Wong, J.J. Niu, A.T. Pearson, D. Laux, D.R. Adkins, A. Pimentel, A.J. Rosenberg, D.L. Richardson, W. Wong, T.A. Kaufmann, K. Katchar, X. Qing, C. Iacobucci, K. Schlienger, D. Pfister
Institutions: University of Alabama at Birmingham, Memorial Sloan Kettering Cancer Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Kansas Medical Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Medical College of Wisconsin, Banner MD Anderson Cancer Center, University of Chicago, University of Iowa, Washington University in St. Louis, University of Miami, Sylvester Comprehensive Cancer Center
Language: English
Field: Medicine
Open Access status: bronze
Funders: Conquer Cancer Foundation, Gateway for Cancer Research, Cancer Research Foundation, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Adenoid Cystic Carcinoma Research Foundation, Regeneron Pharmaceuticals, Exelixis, HCA Healthcare, Actuate Therapeutics, MacroGenics, Rakuten Medical, Coherus Biosciences, Eisai, Astellas Pharma, Fujian Provincial Health Commission, Plexxikon, Genentech, EMD Serono
OpenAlex ID: W4387824814
FWCI: 1.007
Cites:
Cited by: 4
Related to: 10